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Abstract 
Purpose/Objective(s) 
The aim of this study is to determine the impact of image guided radiotherapy (IGRT) in 
breast boost radiotherapy. 
 
Methods and Materials 
CT images from a cohort of 60 patients who received whole breast radiotherapy (WBRT) 
and a tumour bed boost were used to create sequential and concomitant boost treatment 
plans (30 each). Two treatment plans were created for each case using tumour bed planning 
target volume (PTV) margins of 5mm (achieved with IGRT) and 8mm (required for bony 
anatomy verification). Dose data were collected for breast; lung and heart; differences with 
margin size were tested for statistical significance. 
 
Results 
A median decrease of 29 cc (11 cc - 193 cc) of breast tissue receiving 95% of prescribed 
dose was observed where IGRT margins were used. Decreases in doses to lungs, contra-
lateral breast and heart were modest but statistically significant (p<0.01). Concomitant boost 
plan quality was compromised with the 8 mm PTV margin. 
 
Conclusions 
The use of image guidance in breast boost radiotherapy resulted in a modest reduction of 
radiation dose to breast, lung and heart tissues. IGRT is necessary for complex multi-volume 
concomitant boost treatments. 
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Introduction 
Whole breast radiotherapy following breast conserving surgery is standard treatment for 
patients with breast cancer. Patients with a high risk of recurrence receive a radiotherapy 
boost dose to the tumour bed (TB) [1]. Whilst clinical localisation and treatment with electron 
is common, accurate localisation of the tumour bed is achieved only if internal markers are 
used to indicate its position on computed tomography (CT) images [2,3]. This improved 
localisation enables conformal photon dose distributions to be created which deliver the 
boost dose to the tumour bed whilst ensuring the dose to other tissues is not excessive. This 
is relevant particularly for studies in which escalated doses are being tested with sequential 
or integrated boost techniques [4,5]. 
 
Conformal dose distributions and higher boost doses require accurate patient set up and 
robust on-treatment verification regimes. Standard imaging for breast radiotherapy uses 
bony anatomy landmarks for matching from electronic portal images of the megavoltage 
(MV) treatment beam. This is straightforward and widely available, but requires a tumour bed 
surrogate, such as the ribs, as neither the tumour bed and or internal markers, such as 
surgical clips can be visualised on MV images. Imaging at kilovoltage energies is required to 
visualise surgical clips and hence deduce tumour bed positions most accurately with the 
potential to decrease tumour bed Planning Target Volumes (PTV).  
 
Previous work has shown that 5 mm tumour bed PTV margins can be achieved [6,7] with 
Image Guided Radiotherapy (IGRT). The purpose of this work is to evaluate the gain from 
the use of IGRT and reduced margins on breast tissue and organ at risk doses in breast 
boost radiotherapy. 
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Method 
This study forms part of a National Institute for Health Research (NIHR) Efficacy and 
Mechanisms Evaluation (EME) programme investigating image guidance in breast 
radiotherapy and is embedded within the UK IMPORT High trial [4]. Ethical approval was 
granted for the EME study by the Cambridgeshire 4 Research Ethics Committee on 22nd 
October 2010.  
 
 
Target Structures  and Organ at Risk Delineation 
CT planning data sets from sixty patients treated between July 2009 and December 2011, 
within the IMPORT High trial, were selected consecutively from an alphabetical ordered list. 
Surgical clips marking the position of the tumour bed had been inserted at the time of breast 
conserving surgery. The Clinical Target Volume of the tumour bed (CTV_TB) encompassed 
the surgical clips, any seroma and any architectural distortion. Whole breast target volumes 
(WB_TV) were defined from the whole breast treatment fields and excluded the lung and 
ribcage and tissue within 5 mm of the skin surface. This volume is not an ICRU 50/62 
defined PTV; it is used in the IMPORT Trial as a reporting structure and to provide 
consistency across a large numbers of participating centres and clinicians. The ipsilateral 
lung, contralateral lung, heart and contralateral breast were delineated as organs at risk 
structures.  
 
Tumour Bed Planning Target Volume 
The CTV_TB was expanded to create two Planning Target Volumes (PTV_TB) for each data 
set. The first used a 5 mm margin as required by the IMPORT High trial. Coles et al [6] and 
Harris et al [7] have described how image guidance using tumour bed markers and set up 
error correction strategies reduced population set up errors so that a 5 mm tumour bed PTV 
margin was achieved. The second PTV_TB margin was 8 mm. This represents a standard 
bony anatomy verification margin for breast radiotherapy for comparison with the image 
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guidance based margin of 5mm. This margin was derived from an analysis of 1574 images 
where bony anatomy was used as a surrogate for the tumour bed. Systematic errors in 
patient set up were calculated from imaging on fractions 1 to 3 and were corrected on 
fraction 4. 
 
Planning 
30 cases were planned with a sequential conformal photon boost to the tumour bed and 30 
with a concomitant boost. The sequential boost consisted of a Phase 1 whole breast plan of 
40Gy in 15 fractions followed by a Phase 2 of 16Gy in 8 fractions to the tumour bed boost 
volume only. The concomitant boost was delivered in 15 fractions with total dose 36Gy to the 
whole breast via tangential fields; 40Gy to the partial breast and an escalated dose to the 
tumour bed via co-planar conformal fields. The escalated dose was 48Gy or 53Gy 
depending on randomisation. Plan assessment criteria and organ at risk constraints for the 
IMPORT High trial were used to guide the planning (Table 1). Plans were generated using 
1Philips Pinnacle3 v8.0 and v9.0 Treatment planning system using the forward planned 
method described by Donovan et al [8]. The dose calculation used a collapsed cone 
convolution algorithm with 0.25 cm × 0.25 cm × 0.25 cm grid. Beam energy was 6MV 
predominately. 
 
Analysis 
The main metric used to assess the impact of IGRT on breast boost plans was the volume of 
tissue receiving 95% of the tumour bed dose.  In addition, data were collected on doses to the 
lungs, heart and contralateral breast from the plan assessment criteria shown in Table 1 plus 
mean heart and lung doses. The data were tested for normality and the Wilcoxon signed ranks 
test used to test for the statistical significance of the differences in the metrics between plans 
with 5 mm and 8 mm PTV_TB margins. Data were dichotomised by tumour bed laterality and 
the Mann-Whitney test statistic used to determine the statistical significance of any differences.   
                                                 
1
 Philips Healthcare, Netherlands 
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Results 
35 patients had left side and 25 right side disease. The median (range) of CTV_TB volume 
was 10.2 cc (2.4 cc – 205.0 cc). There was no statistical significant difference in CTV_TB or 
PTV_TB volumes (grouped into 5mm or 8 mm) between the sequential and concomitant 
boost plans, or the concomitant boost plans at 48Gy or 53Gy.   
 
Effect on breast tissue 
Table 2 summarises the volumes of breast tissue receiving 95% of the tumour bed dose. 
The absolute volumes of breast tissue receiving a high dose were statistically significantly 
different between the two plan types (p < 0.01); the volumes were larger in the sequential 
boost plans. The magnitude of the change in volume between a PTV_TB of 5 mm to that of 
8 mm was not different between sequential and concomitant boost plans; between left and 
right breasts, or between the 48Gy and 53Gy boost dose. The difference data were 
combined and the median decrease in the high dose volume, if IGRT was used, was 29 cc 
(range 11 to 193 cc). This equates to an additional 3.3% (median) up to 11.8% (maximum) 
of the whole breast being spared high dose irradiation for these boost treatments from the 
use of image guidance. 
 
Organs at Risk 
As anticipated, all dose measures for the organs at risk increased with the use of the 8 mm 
standard verification margin, albeit modestly (Table 3). Only mean heart dose and V13Gy for 
the heart had a statistically significant association with tumour bed laterality (p < 0.01); 
values were higher in the left breast group.   
 
Impact on treatment plans 
Where the image guided margin of 5 mm was used, 56 cases met all planning objectives. In 
the remaining 4 cases the minimum dose coverage of the tumour bed was below 95% 
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(above 91%). These were all left breast treatment where the tumour bed and chest wall were 
in close proximity, the PTV_TB extended into lung and overlay the heart (see Figure 2); a 
compromise was accepted between coverage and heart dose for the clinical treatment. As 
the IMPORT High plan objectives were set for a 5mm PTV_TB it was expected the 
increasing the margin to 8 mm would cause more plans to fail.  This occurred only for the 
concomitant boost plans where 10 plans breached a mandatory constraint. In 8 of these the 
PTV_TB coverage was below 95% (between 91% and 94%); in the other 2 the maximum 
dose in the whole breast volume exceeded the specified volume limit (by 2% in one case 
and 5% in the other). In 9 cases the advised limit of 40 to 44Gy median dose to the partial 
breast was exceeded by 0.5Gy to 3.7Gy. 
 
 
Discussion 
The purpose of this work was to evaluate the impact of image guidance on normal tissue 
doses in breast boost radiotherapy. Image guidance enables smaller PTV margins as 
population set up errors are reduced. We have shown that a reduction of 29 cc (11 cc – 193 
cc) in breast tissue receiving a high dose is obtained using internal markers, image guidance 
and a PTV_TB margin of 5 mm compared to an 8 mm margin based bony anatomy with a 
standard verification protocol.  
 
Evidence suggests that there is a dose/volume relationship for normal tissue toxicity in 
breast tissue however these dose/volume constraints have yet to be quantified [9] and it is 
unclear what effect is expected at the dose levels and volumes we report. Bartelink et al. [10] 
reported that by administering a boost of 16 Gy following WBRT of 50 Gy, rates of fibrosis 
increased by approximately 15% from 13.2% (no boost group) to 28.1% at 10 years. 
Patients in the Bartelink study had a PTV margin of 1.5 cm compared to our much smaller 
values of 5 and 8 mm. The sequential boost prescription used in this study was 16Gy in 2Gy 
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fractions hence we predict a lower rate of fibrosis that than in the EORTC study, given the 
smaller volumes irradiated to high dose.  
 
The impact of the larger PTV_TB margin was modest on the reported organ at risk doses 
cases for both sequential and concomitant boost plans. The delivery of the majority of the 
therapeutic dose was via standard tangential fields thus maintaining organ at risk sparing, 
even in these complex situations with an increased PTV_TV margin. The implications of the 
recent work by Darby et al [11] are that even the small changes in mean heart dose 
presented here are important given the linear relationship between mean heart dose and 
Major Coronary Events (MCE). With tens of thousands of women presenting for breast 
cancer radiotherapy each year, and good survival rates, a modest change in mean heart is 
not a trivial change in the predicted absolute numbers of MCE within the population. 
 
A particularly interesting finding was the difficulty in meeting the set planning criteria in the 
three volume concomitant boost plans when the PTV_TB margin was changed by only 3mm. 
Coverage of the three planning target volumes was compromised, specifically the median 
dose in the partial breast (9 cases). This is important as the IMPORT High trial requires 
discrimination between the dose levels of the whole, partial and tumour bed regions of the 
breast. This work shows image guidance is necessary to achieve concomitant breast boost 
plans of this complexity. This is in addition to its benefits in reducing tissue doses. 
 
Conclusion  
The use of image guidance in breast boost radiotherapy is necessary to achieve 
discrimination between dose levels in three volume, complex plans. It results in modest 
reductions in radiation doses to breast, lung and heart tissues for both sequential and 
concomitant boost treatments.   
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Table 1 
Plan Assessment - Sequential Boost – Target Volumes 
 
Target  Minimum Dose Median Dose Maximum Dose 
Whole breast 
 
> 90% volume > 36 Gy 40 to 44 Gy  < 5% volume > 56 Gy 
Tumour bed PTV > 95% volume > 53.2Gy 
 
55.5 to 56.5 Gy < 5% volume > 60 Gy 
 
Plan Assessment - Concomitant Boost – Target Volumes 
Target  Minimum Dose Median Dose Maximum Dose 
Whole breast  
 
> 90% volume > 32.4 Gy 34 to 37 Gy  < 5% volume > 40 Gy 
Partial breast PTV 
 
> 90% volume > 36 Gy 40 to 44 Gy   
Tumour bed PTV 
 
> 95% volume > 45.6Gy 
or 
> 95% volume > 50.4Gy 
47.5 to 48.5 Gy 
or 
52.5 to 53.5 Gy 
< 3% volume > 
51.4Gy or 
< 3% volume > 
56.7Gy 
 
Plan Assessment – Organs at Risk Planning Constraints 
   
Organ at Risk Dose (Gy) Maximum Allowed Volume (%) 
Ipsilateral Lung 18 15 
Contralateral Lung 2.5 15 
Heart 13 10 
Contralateral 
Breast 
Mean Dose < 0.5Gy Permitted Maximum Mean Dose 1.5 Gy 
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Table 2 
Volume of breast tissue receiving 95% of the tumour bed prescription dose for 
5mm and 8mm PTV_TB margins for sequential and concomitant boost plans. 
Data are given as median (range) and presented in absolute volume (cc) and as 
a percentage of the whole breast volume.  
 
 
 PTV_TB = 5mm PTV_TB = 8mm Difference 
High dose volume (cc) 
   
 
Sequential boost 
 
91 (30 – 863) 
 
125 (42 – 1005) 
 
33 (11 – 193) 
 
Concomitant boost 
 
60 (19 -  228) 
 
87 (30 – 260) 
 
23 (11 - 66) 
 
Percentage of whole 
breast volume (%) 
   
 
Sequential boost 
 
10 (4 – 35) 
 
14 (5 - 41) 
 
4 (2 – 12) 
 
Concomitant boost 
 
8 ( 2 – 19) 
 
11 (4 – 24) 
 
3 (1 – 6)  
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Table 3 
Dosimetric data given as median (minimum , maximum) for each parameter for 
ipsilateral and contralateral lungs. Data in bold indicate where differences were 
statistically significant (P< 0.01). 
 
 
 PTV_TB = 5 mm PTV_TB = 8 mm Difference 
Ipsilateral lung V18Gy (%) 
 
9.6 (1.9 , 27.6) 10.0 (2.3 , 27.8) 0.3 (-0.9 , 5.0) 
 
Ipsilateral lung mean dose (Gy) 
 
5.6 (2.6 , 11.3) 
 
6.1 (2.8 , 11.5) 
 
0.3 (-0.7 , 2.7) 
 
Contralateral lung V2.5Gy (%) 
Sequential boost 
Concomitant boost 
 
0.0 (0.0 , 12.2) 
1.6 (0.0 , 13.4) 
 
 
0.1 (0.0 , 13.9) 
3.2 (0.0 , 17.4) 
 
0.0 (-3.3 , 7.5) 
1.0 (-2.5 , 16.1) 
Contralateral lung mean dose (Gy) 
 
0.4 (0.1 , 1.2) 
 
0.5 (0.1 , 3.3) 
 
0.1 (-0.2 , 3.1) 
 
Contralateral breast mean dose (Gy) 
 
5.0 (0.0 , 1.8) 5.0 (0.0 , 1.4) 0.1 (-1.3 , 0.4) 
Heart mean dose (Gy 
Right breast cases 
Left breast cases 
 
1.2 (0.4 , 2.2) 
1.9 (0.6 , 5.1) 
 
1.4 (0.5 , 2.6) 
2.1 (0.6 , 6.0) 
 
0.2 (-0.3 , 1.6) 
0.2 (-0.2 , 1.0) 
Heart V13Gy (%) 
Right breast cases 
Left breast cases 
 
0.0 (0.0 , 0.0) 
0.2 (0.0 , 5.5) 
 
0.0 (0.0 , 0.2) 
0.4 (0.0 , 6.3) 
 
0.0 (0.0 , 0.2) 
0.1 (-0.1, 2.4) 
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Figure Captions 
 
Figure 1: Axial (a) and sagittal (b) views to show CTV_TB (red),  PTV_TB = 5 
mm (yellow) and 95% isodose line (light green), PTV_TB = 8 mm (sky blue), and 
95% isodose line (dark green). Small circles indicate tumour bed surgical clips. 
 
Figure 2 : A shows the original PTV_TB with 5mm margin in close proximity to 
lung. Increasing the PTV_TB by 3 mm means it expands into the lung (B) and to 
achieve coverage requires an increase in the tangential field (C) and the heart 
dose will increase.
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Figure 1 
(a)  (b)     
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